

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

X



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Medical & Appointments](#) & Treatment

[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Jae Park, MD

[Leukemia Specialist & Cellular Therapist \(#about-me\)](#)



Areas of Expertise

Conditions I Treat

- Leukemia
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)

My Specialties

- Clinical trials
- Cellular therapy
- Immunotherapy

[View more expertise \(#about_specialties\)](#)



[Dr. Park's Office Information \(#contact-and-location\)](#)



Languages: English & Korean

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9154](#)

[Make an appointment](#)

Get to Know Me

I am a hematologist-oncologist specializing in the care of patients with leukemia. Along with other colleagues on the Leukemia Service at Memorial Sloan Kettering Cancer Center, I am dedicated to providing the best possible care by treating each patient as if he or she were a member of my own family.

What I Do at MSK

I'm a leukemia specialist, which is a doctor with special training in diagnosing and treating leukemia (loo-KEE-mee-uh). This cancer starts in tissue that forms blood, such as bone marrow.

A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.

- Chief, Cellular Therapy Service

Areas of Expertise

Conditions I Treat

- Leukemia
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Acute promyelocytic leukemia (APL)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- Myeloproliferative neoplasms (MPN)/Myeloproliferative disorders
- Hairy cell leukemia (HCL)
- Systemic mastocytosis
- Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder
- Blood, bone marrow, and hematologic cancers and conditions

My Specialties

- Clinical trials
- Cellular therapy
- Immunotherapy

Education & Honors

Education

- MD, Johns Hopkins School of Medicine

Residencies

- Internal Medicine - Massachusetts General Hospital

Fellowships

- Medical Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

- Internal Medicine
- Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](#) .

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call [646-497-9154](#) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

Contact and Location

Office Phone

 [646-608-3743](tel:646-608-3743)

Location

 New York, NY

[David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center](#)

 530 East 74th Street

New York, NY 10021

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Cellular Therapy Service doctors \(\[https://www.mskcc.org/doctor#f:Departments=\\[Medicine,Division of Hematologic Malignancies,Cellular Therapy Service\\]\]\(https://www.mskcc.org/doctor#f:Departments=\[Medicine,Division of Hematologic Malignancies,Cellular Therapy Service\]\)\)](#)

See all Leukemia Service doctors ([https://www.mskcc.org/doctor#f:Departments=\[Medicine,Division of Hematologic Malignancies,Leukemia Service\]](https://www.mskcc.org/doctor#f:Departments=[Medicine,Division of Hematologic Malignancies,Leukemia Service]))

Clinical Trials

- Clinical Trials Investigated by Dr. Park
- [A Phase 1 Study of 19-28z/IL-18 CAR T Cell Therapy in People With Acute Lymphoblastic Leukemia](#)
- [A Phase 1 Study of ADCLEC.syn1 CAR T Cell Therapy in People With Acute Myeloid Leukemia](#)
- [A Phase 1-2 Study of CABA-201 CAR T Cell Therapy to Treat Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy](#)
- [A Phase 1-2 Study of JCAR017 CAR T Cell Therapy in People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](#)



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](#) (<https://www.mskcc.org/cancer-care/clinical-trials>)

Research and Publications

[Park JH, Tallman MS. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?. Expert Rev Hematol. 2011 Aug;4\(4\):427-36.](#)

[Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-](#)

[trans retinoic acid. Blood. 2011 Aug 4; 118\(5\):1248-54.](#)

[Park JH, Hedvat CV, Tallman MS. Blood consult: acute myeloid leukemia and the t\(8;21\)\(q22;22\). Blood. 2011 Mar 10;117\(10\):2775-7.](#)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Jae Park discloses the following relationships and financial interests:

- Adaptive Biotechnologies Corp
Professional Services and Activities
- Affyimmune Therapeutics, Inc.
Professional Services and Activities
- Allogene Therapeutics
Professional Services and Activities
- Amgen
Professional Services and Activities
- Artiva Biotherapeutics, Inc.
Professional Services and Activities
- Ascentage Pharma
Professional Services and Activities
- Autolus Therapeutics
Professional Services and Activities
- Bright Pharmaceuticals
Professional Services and Activities
- Bristol-Myers Squibb

Professional Services and Activities

- Curocell Inc.

Professional Services and Activities

- Iovance Biotherapeutics, Inc.

Professional Services and Activities

- Jazz Pharmaceuticals

Professional Services and Activities

- Kite Pharmaceuticals

Professional Services and Activities

- Servier

Professional Services and Activities

- Synthekine, Inc.

Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2025 Memorial Sloan Kettering Cancer Center